Erythropoietin and its angiogenic activity

International Journal of Molecular Sciences

Volumn 18, Issue 7, 2017, Pages

  Kimáková, Patrícia ^a   Solár, Peter ^a   Solárová, Zuzana ^a   Komel, Radovan ^b   Debeljak, Nataša ^b  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Angiogenesis; Cancer; Endothelial; Erythropoietin; Erythropoietin receptor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ION; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; JANUS KINASE 2; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE C GAMMA1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; STAT5 PROTEIN; TUMOR NECROSIS FACTOR; VANILLOID RECEPTOR 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADIPOSE TISSUE; ANGIOGENESIS; APOPTOSIS; BONE MARROW; CELL DIFFERENTIATION; CELL GROWTH; ENDOTHELIUM CELL; ERYTHROCYTE; GROWTH STIMULATION; HEART TISSUE; HUMAN; INTRACELLULAR SIGNALING; LEG ISCHEMIA; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINOPATHY; REVIEW; TUMOR PROMOTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; METABOLISM; NEOPLASM;

ANIMALS; ERYTHROPOIETIN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SPECIFICITY;

EID: 85024115042     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18071519     Document Type: Review

References (101)

1. Jelkmann, W. Erythropoietin: Structure, control of production, and function. Physiol. Rev. 1992, 72, 449-489. [PubMed]
2. Lin, C.S.; Lim, S.K.; D’Agati, V.; Costantini, F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996, 10, 154-164. [CrossRef] [PubMed]
3. Krantz, S.B. Erythropoietin. Blood 1991, 77, 419-434. [PubMed]
4. Hardee, M.E.; Arcasoy, M.O.; Blackwell, K.L.; Kirkpatrick, J.P.; Dewhirst, M.W. Erythropoietin biology in cancer. Clin. Cancer Res. 2006, 12, 332-339. [CrossRef] [PubMed]
5. Watowich, S.S.; Hilton, D.J.; Lodish, H.F. Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol. Cell. Biol. 1994, 14, 3535-3549. [CrossRef] [PubMed]
6. Pelekanou, V.; Kampa, M.; Kafousi, M.; Dambaki, K.; Darivianaki, K.; Vrekoussis, T.; Sanidas, E.; Tsiftsis, D.D.; Stathopoulos, E.N.; Castanas, E. Erythropoietin and its receptor in breast cancer: Correlation with steroid receptors and outcome. Cancer Epidemiol. Biomark. Prev. 2007, 16, 2016-2023. [CrossRef] [PubMed]
7. Darnell, J.E., Jr.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415-1421. [CrossRef] [PubMed]
8. Janmaat, M.L.; Heerkens, J.L.; de Bruin, A.M.; Klous, A.; deWaard, V.; de Vries, C.J. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115, 1453-1460. [CrossRef] [PubMed]
9. Haller, H.; Christel, C.; Dannenberg, L.; Thiele, P.; Lindschau, C.; Luft, F.C. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996, 50, 481-488. [CrossRef] [PubMed]
10. Carlini, R.G.; Dusso, A.S.; Obialo, C.I.; Alvarez, U.M.; Rothstein, M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993, 43, 1010-1014. [CrossRef] [PubMed]
11. Carlini, R.G.; Reyes, A.A.; Rothstein, M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995, 47, 740-745. [CrossRef] [PubMed]
12. Anagnostou, A.; Lee, E.S.; Kessimian, N.; Levinson, R.; Steiner, M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 1990, 87, 5978-5982. [CrossRef] [PubMed]
13. Anagnostou, A.; Liu, Z.; Steiner, M.; Chin, K.; Lee, E.S.; Kessimian, N.; Noguchi, C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994, 91, 3974-3978. [CrossRef] [PubMed]
14. Noguchi, C.T.; Wang, L.; Rogers, H.M.; Teng, R.; Jia, Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev. Mol. Med. 2008, 10, e36. [CrossRef] [PubMed]
15. Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.; Mildner-Rihm, C.; Martin, H.; Zeiher, A.M.; Dimmeler, S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102, 1340-1346. [CrossRef] [PubMed]
16. Santhanam, A.V.; d’Uscio, L.V.; Peterson, T.E.; Katusic, Z.S. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008, 29, 1451-1455. [CrossRef] [PubMed]
17. Westenbrink, B.D.; Lipsic, E.; van der Meer, P.; van der Harst, P.; Oeseburg, H.; Du Marchie Sarvaas, G.J.; Koster, J.; Voors, A.A.; van Veldhuisen, D.J.; van Gilst, W.H.; et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 2007, 28, 2018-2027. [CrossRef] [PubMed]
18. Brines, M.; Cerami, A. Discovering erythropoietin’s extra-hematopoietic functions: Biology and clinical promise. Kidney Int. 2006, 70, 246-250. [CrossRef] [PubMed]
19. Yang, J.; Xiao, Z.; Li, T.; Gu, X.; Fan, B. Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int. J. Oncol. 2012, 40, 1230-1237. [PubMed]
20. Kawachi, K.; Iso, Y.; Sato, T.; Wakabayashi, K.; Kobayashi, Y.; Takeyama, Y.; Suzuki, H. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessel. 2012, 27, 79-88. [CrossRef] [PubMed]
21. Ahn, S.; Min, S.K.; Min, S.I.; Suh, J.H.; Kim, S.J.; Ha, J. Early sustained injections of erythropoietin improve angiogenesis and restoration of perfusion in the ischemic mouse hindlimb. J. Korean Med. Sci. 2012, 27, 1073-1078. [CrossRef] [PubMed]
22. Ribatti, D.; Presta, M.; Vacca, A.; Ria, R.; Giuliani, R.; Dell’Era, P.; Nico, B.; Roncali, L.; Dammacco, F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93, 2627-2636. [PubMed]
23. Yamaji, R.; Okada, T.; Moriya, M.; Naito, M.; Tsuruo, T.; Miyatake, K.; Nakano, Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur. J. Biochem. 1996, 239, 494-500. [CrossRef] [PubMed]
24. Hu, D.E.; Hiley, C.R.; Fan, T.P. Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Br. J. Pharmacol. 1996, 117, 545-551. [CrossRef] [PubMed]
25. Ashley, R.A.; Dubuque, S.H.; Dvorak, B.;Woodward, S.S.;Williams, S.K.; Kling, P.J. Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr. Res. 2002, 51, 472-478. [CrossRef] [PubMed]
26. Alvarez Arroyo, M.V.; Castilla, M.A.; Gonzalez Pacheco, F.R.; Tan, D.; Riesco, A.; Casado, S.; Caramelo, C. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J. Am. Soc. Nephrol. 1998, 9, 1998-2004. [PubMed]
27. Beleslin-Cokic, B.B.; Cokic, V.P.; Yu, X.; Weksler, B.B.; Schechter, A.N.; Noguchi, C.T. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004, 104, 2073-2080. [CrossRef] [PubMed]
28. Casas, A.; Di Venosa, G.; Hasan, T.; Al, B. Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 2011, 18, 2486-2515. [CrossRef] [PubMed]
29. Yu, Y.B.; Su, K.H.; Kou, Y.R.; Guo, B.C.; Lee, K.I.;Wei, J.; Lee, T.S. Role of transient receptor potential vanilloid 1 in regulating erythropoietin-induced activation of endothelial nitric oxide synthase. Acta Physiol. 2016, 219, 465-477. [CrossRef] [PubMed]
30. Xiao, J.W.; Li, L.H.; Hong, B.Z.; Xiao, J.Q.;Wei, D.M.; Jin, Z. Therapeutic effects and related mechanisms of erythropoietin sustained-release gelatin hydrogel microspheres on a murine model of hindlimb ischemia. Zhonghua Xin Xue Guan Bing Za Zhi 2016, 44, 524-529. [PubMed]
31. Su, K.H.; Shyue, S.K.; Kou, Y.R.; Ching, L.C.; Chiang, A.N.; Yu, Y.B.; Chen, C.Y.; Pan, C.C.; Lee, T.S. β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J. Cell. Physiol. 2011, 226, 3330-3339. [CrossRef] [PubMed]
32. Lamanuzzi, A.; Saltarella, I.; Ferrucci, A.; Ria, R.; Ruggieri, S.; Racanelli, V.; Rao, L.; Annese, T.; Nico, B.; Vacca, A.; Ribatti, D. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients. Oncotarget 2016, 7, 14510-14521. [PubMed]
33. De Luisi, A.; Binetti, L.; Ria, R.; Ruggieri, S.; Berardi, S.; Catacchio, I.; Racanelli, V.; Pavone, V.; Rossini, B.; Vacca, A.; Ribatti, D. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma. Angiogenesis 2013, 16, 963-973. [CrossRef] [PubMed]
34. Su, J.; Li, Z.; Cui, S.; Ji, L.; Geng, H.; Chai, K.; Ma, X.; Bai, Z.; Yang, Y.; Wuren, T.; Ge, R.L.; Rondina, M.T. The local HIF-2α/EPO pathway in the bone marrow is associated with excessive erythrocytosis and the increase in bone marrow microvessel density in chronic mountain sickness. High Alt. Med. Biol. 2015, 16, 318-330. [CrossRef] [PubMed]
35. Wan, L.; Zhang, F.; He, Q.; Tsang, W.P.; Lu, L.; Li, Q.; Wu, Z.; Qiu, G.; Zhou, G.; Wan, C. EPO promotes bone repair through enhanced cartilaginous callus formation and angiogenesis. PLoS ONE 2014, 9, e102010. [CrossRef] [PubMed]
36. Holstein, J.H.; Orth, M.; Scheuer, C.; Tami, A.; Becker, S.C.; Garcia, P.; Histing, T.; Morsdorf, P.; Klein, M.; Pohlemann, T.; Menger, M.D. Erythropoietin stimulates bone formation, cell proliferation, and angiogenesis in a femoral segmental defect model in mice. Bone 2011, 49, 1037-1045. [CrossRef] [PubMed]
37. Luk, C.T.; Shi, S.Y.; Choi, D.; Cai, E.P.; Schroer, S.A.; Woo, M. In vivo knockdown of adipocyte erythropoietin receptor does not alter glucose or energy homeostasis. Endocrinology 2013, 154, 3652-3659. [CrossRef] [PubMed]
38. Mikolas, E.; Cseh, J.; Pap, M.; Szijarto, I.A.; Balogh, A.; Laczy, B.; Beko, V.; Fisi, V.; Molnar, G.A.; Merei, A.; et al. Effects of erythropoietin on glucose metabolism. Horm Metab. Res. 2012, 44, 279-285. [CrossRef] [PubMed]
39. Hamed, S.; Egozi, D.; Kruchevsky, D.; Teot, L.; Gilhar, A.; Ullmann, Y. Erythropoietin improves the survival of fat tissue after its transplantation in nude mice. PLoS ONE 2010, 5, e13986. [CrossRef] [PubMed]
40. Elsherbiny, A.; Hogger, D.C.; Borozadi, M.K.; Schmidt, C.A.; Plock, J.; Largo, R.D.; Lindenblatt, N.; Giovanoli, P.; Contaldo, C. EPO reverses defective wound repair in hypercholesterolaemic mice by increasing functional angiogenesis. J. Plast. Reconstr. Aesthet. Surg. 2012, 65, 1559-1568. [CrossRef] [PubMed]
41. Teng, R.; Gavrilova, O.; Suzuki, N.; Chanturiya, T.; Schimel, D.; Hugendubler, L.; Mammen, S.; Yver, D.R.; Cushman, S.W.; Mueller, E.; et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat. Commun. 2001, 2, 520. [CrossRef] [PubMed]
42. Westenbrink, B.D.; Oeseburg, H.; Kleijn, L.; van der Harst, P.; Belonje, A.M.; Voors, A.A.; Schoemaker, R.G.; de Boer, R.A.; van Veldhuisen, D.J.; van Gilst, W.H. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc. Drugs Ther. 2008, 22, 265-274. [CrossRef] [PubMed]
43. Imamura, R.; Moriyama, T.; Isaka, Y.; Namba, Y.; Ichimaru, N.; Takahara, S.; Okuyama, A. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1α. Transplantation 2007, 83, 1371-1379. [CrossRef] [PubMed]
44. Wang, L.; Zhang, Z.; Wang, Y.; Zhang, R.; Chopp, M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35, 1732-1737. [CrossRef] [PubMed]
45. Nakano, M.; Satoh, K.; Fukumoto, Y.; Ito, Y.; Kagaya, Y.; Ishii, N.; Sugamura, K.; Shimokawa, H. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ. Res. 2007, 100, 662-669. [CrossRef] [PubMed]
46. Zentilin, L.; Tafuro, S.; Zacchigna, S.; Arsic, N.; Pattarini, L.; Sinigaglia, M.; Giacca, M. Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 2006, 107, 3546-3554. [CrossRef] [PubMed]
47. Satoh, K.; Fukumoto, Y.; Nakano, M.; Kagaya, Y.; Shimokawa, H. Emergence of the erythropoietin/ erythropoietin receptor system as a novel cardiovascular therapeutic target. J. Cardiovasc. Pharmacol. 2011, 58, 570-574. [CrossRef] [PubMed]
48. Sanchis-Gomar, F.; Garcia-Gimenez, J.L.; Pareja-Galeano, H.; Romagnoli, M.; Perez-Quilis, C.; Lippi, G. Erythropoietin and the heart: Physiological effects and the therapeutic perspective. Int. J. Cardiol. 2014, 171, 116-125. [CrossRef] [PubMed]
49. Kobayashi, H.; Miura, T.; Ishida, H.; Miki, T.; Tanno, M.; Yano, T.; Sato, T.; Hotta, H.; Shimamoto, K. Limitation of infarct size by erythropoietin is associated with translocation of AKT to the mitochondria after reperfusion. Clin. Exp. Pharmacol. Physiol. 2008, 35, 812-819. [CrossRef] [PubMed]
50. Hu, X.; Yu, S.P.; Fraser, J.L.; Lu, Z.; Ogle, M.E.;Wang, J.A.;Wei, L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg. 2008, 135, 799-808. [CrossRef] [PubMed]
51. Lu, J.; Yao, Y.Y.; Dai, Q.M.; Ma, G.S.; Zhang, S.F.; Cao, L.; Ren, L.Q.; Liu, N.F. Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats. Cardiovasc. Diabetol. 2012, 11, 105. [CrossRef] [PubMed]
52. Joshi, D.; Tsui, J.; Ho, T.K.; Selvakumar, S.; Abraham, D.J.; Baker, D.M. Review of the role of erythropoietin in critical leg ischemia. Angiology 2010, 61, 541-550. [CrossRef] [PubMed]
53. Bennis, Y.; Sarlon-Bartoli, G.; Guillet, B.; Lucas, L.; Pellegrini, L.; Velly, L.; Blot-Chabaud, M.; Dignat-Georges, F.; Sabatier, F.; Pisano, P. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J. Thromb. Haemost. 2012, 10, 1914-1928. [CrossRef] [PubMed]
54. Li, H.G.; Li, J.S.; Chen, W.L.; Wang, L.; Wu, D.H.; Lin, Z.Y. Prognostic significance of erythropoietin and erythropoietin receptor in tongue squamous cell carcinoma. Br. J. Oral Maxillofac. Surg. 2009, 47, 470-475. [CrossRef] [PubMed]
55. Yu, J.; deMuinck, E.D.; Zhuang, Z.; Drinane, M.; Kauser, K.; Rubanyi, G.M.; Qian, H.S.; Murata, T.; Escalante, B.; Sessa, W.C. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc. Natl. Acad. Sci. USA 2005, 102, 10999-11004. [CrossRef] [PubMed]
56. Kupatt, C.; Hinkel, R.; von Bruhl, M.L.; Pohl, T.; Horstkotte, J.; Raake, P.; El Aouni, C.; Thein, E.; Dimmeler, S.; Feron, O.; et al. Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. J. Am. Coll. Cardiol. 2007, 49, 1575-1584. [CrossRef] [PubMed]
57. Kato, S.; Amano, H.; Ito, Y.; Eshima, K.; Aoyama, N.; Tamaki, H.; Sakagami, H.; Satoh, Y.; Izumi, T.; Majima, M. Effect of erythropoietin on angiogenesis with the increased adhesion of platelets to the microvessels in the hind-limb ischemia model in mice. J. Pharmacol. Sci. 2010, 112, 167-175. [CrossRef] [PubMed]
58. Chen, J.; Connor, K.M.; Aderman, C.M.; Smith, L.E. Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Investig. 2008, 118, 526-533. [CrossRef] [PubMed]
59. Grant, M.B.; May, W.S.; Caballero, S.; Brown, G.A.; Guthrie, S.M.; Mames, R.N.; Byrne, B.J.; Vaught, T.; Spoerri, P.E.; Peck, A.B.; et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat. Med. 2002, 8, 607-612. [CrossRef] [PubMed]
60. Otani, A.; Kinder, K.; Ewalt, K.; Otero, F.J.; Schimmel, P.; Friedlander, M. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat. Med. 2002, 8, 1004-1010. [CrossRef] [PubMed]
61. Ritter, M.R.; Banin, E.; Moreno, S.K.; Aguilar, E.; Dorrell, M.I.; Friedlander, M. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J. Clin. Investig. 2006, 116, 3266-3276. [CrossRef] [PubMed]
62. Checchin, D.; Sennlaub, F.; Levavasseur, E.; Leduc, M.; Chemtob, S. Potential role of microglia in retinal blood vessel formation. Investig. Ophthalmol. Vis. Sci. 2006, 47, 3595-3602. [CrossRef] [PubMed]
63. Watanabe, D.; Suzuma, K.; Matsui, S.; Kurimoto, M.; Kiryu, J.; Kita, M.; Suzuma, I.; Ohashi, H.; Ojima, T.; Murakami, T.; et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 2005, 353, 782-792. [CrossRef] [PubMed]
64. Chen, J.; Connor, K.M.; Aderman, C.M.; Willett, K.L.; Aspegren, O.P.; Smith, L.E. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Investig. Ophthalmol. Vis. Sci. 2009, 50, 1329-1335. [CrossRef] [PubMed]
65. Eldweik, L.; Mantagos, I.S. Role of VEGF inhibition in the treatment of retinopathy of prematurity. Semin. Ophthalmol. 2016, 31, 163-168. [CrossRef] [PubMed]
66. VanWijngaarden, P.; Brereton, H.M.; Gibbins, I.L.; Coster, D.J.;Williams, K.A. Kinetics of strain-dependent differential gene expression in oxygen-induced retinopathy in the rat. Exp. Eye Res. 2007, 85, 508-517. [CrossRef] [PubMed]
67. Caprara, C.; Britschgi, C.; Samardzija, M.; Grimm, C. The erythropoietin receptor is not required for the development, function, and aging of rods and cells in the retinal periphery. Mol. Vis. 2014, 20, 307-324. [PubMed]
68. Yang, Z.; Wang, H.; Jiang, Y.; Hartnett, M.E. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. Am. J. Pathol. 2014, 184, 1230-1239. [CrossRef] [PubMed]
69. Cavallaro, G.; Filippi, L.; Bagnoli, P.; La Marca, G.; Cristofori, G.; Raffaeli, G.; Padrini, L.; Araimo, G.; Fumagalli, M.; Groppo, M.; et al. The pathophysiology of retinopathy of prematurity: An update of previous and recent knowledge. Acta Ophthalmol. 2014, 92, 2-20. [CrossRef] [PubMed]
70. Li, Y.; Lu, Z.; Keogh, C.L.; Yu, S.P.; Wei, L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J. Cereb. Blood Flow Metab. 2006, 27, 1043-1054. [CrossRef] [PubMed]
71. Li, Y.; Lu, Z.Y.; Ogle, M.; Wei, L. Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice. Neurochem. Res. 2007, 32, 2132-2141. [CrossRef] [PubMed]
72. Yan, F.; Zhang, M.; Meng, Y.; Li, H.; Yu, L.; Fu, X.; Tang, Y.; Jiang, C. Erythropoietin improves hypoxic-ischemic encephalopathy in neonatal rats after short-term anoxia by enhancing angiogenesis. Brain Res. 2016, 1651, 104-113. [CrossRef] [PubMed]
73. Xiong, Y.; Zhang, Y.; Mahmood, A.; Meng, Y.; Qu, C.; Chopp, M. Erythropoietin mediates neurobehavioral recovery and neurovascular remodeling following traumatic brain injury in rats by increasing expression of vascular endothelial growth factor. Transl. Stroke Res. 2011, 2, 619-632. [CrossRef] [PubMed]
74. Wang, L.; Chopp, M.; Teng, H.; Bolz, M.; Francisco, M.A.; Aluigi, D.M.; Wang, X.L.; Zhang, R.L.; Chrsitensen, S.; Sager, T.N.; et al. Tumor necrosis factor α primes cerebral endothelial cells for erythropoietin-induced angiogenesis. J. Cereb. Blood Flow Metab. 2011, 31, 640-647. [CrossRef] [PubMed]
75. Miyake, M.; Goodison, S.; Lawton, A.; Zhang, G.; Gomes-Giacoia, E.; Rosser, C.J. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J. Hematol. Oncol. 2013, 6, 65. [CrossRef] [PubMed]
76. El Hasnaoui-Saadani, R.; Pichon, A.; Marchant, D.; Olivier, P.; Launay, T.; Quidu, P.; Beaudry, M.; Duvallet, A.; Richalet, J.P.; Favret, F. Cerebral adaptations to chronic anemia in a model of erythropoietin-deficient mice exposed to hypoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R801-R811. [CrossRef] [PubMed]
77. Pichon, A.; Jeton, F.; El Hasnaoui-Saadani, R.; Hagstrom, L.; Launay, T.; Beaudry, M.; Marchant, D.; Quidu, P.; Macarlupu, J.L.; Favret, F.; et al. Erythropoietin and the use of a transgenic model of erythropoietin-deficient mice. Hypoxia 2016, 4, 29-39. [PubMed]
78. Lee, S.T.; Chu, K.; Park, J.E.; Jung, K.H.; Jeon, D.; Lim, J.Y.; Lee, S.K.; Kim, M.; Roh, J.K. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-β burden in Alzheimer’s disease models. J. Neurochem. 2012, 120, 115-124. [CrossRef] [PubMed]
79. Rangarajan, V.; Juul, S.E. Erythropoietin: Emerging role of erythropoietin in neonatal neuroprotection. Pediatr. Neurol. 2014, 51, 481-488. [CrossRef] [PubMed]
80. Yasuda, Y.; Fujita, Y.; Musha, T.; Tanaka, H.; Shiokawa, S.; Nakamatsu, K.; Mori, S.; Matsuo, T.; Nakamura, Y. Expression of erythropoietin in human female reproductive organs. Ital. J. Anat. Embryol. 2001, 106, 215-222. [PubMed]
81. Yasuda, Y.; Fujita, Y.; Masuda, S.; Musha, T.; Ueda, K.; Tanaka, H.; Fujita, H.; Matsuo, T.; Nagao, M.; Sasaki, R.; et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002, 23, 1797-1805. [CrossRef] [PubMed]
82. Hardee, M.E.; Cao, Y.; Fu, P.; Jiang, X.; Zhao, Y.; Rabbani, Z.N.; Vujaskovic, Z.; Dewhirst, M.W.; Arcasoy, M.O. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007, 2, e549. [CrossRef] [PubMed]
83. Yasuda, Y.; Fujita, Y.; Matsuo, T.; Koinuma, S.; Hara, S.; Tazaki, A.; Onozaki, M.; Hashimoto, M.; Musha, T.; Ogawa, K.; et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003, 24, 1021-1029. [CrossRef] [PubMed]
84. Nakamatsu, K.; Nishimura, Y.; Suzuki, M.; Kanamori, S.; Maenishi, O.; Yasuda, Y. Erythropoietin/ erythropoietin-receptor system as an angiogenic factor in chemically induced murine hepatic tumors. Int. J. Clin. Oncol. 2004, 9, 184-188. [CrossRef] [PubMed]
85. Okazaki, T.; Ebihara, S.; Asada, M.; Yamanda, S.; Niu, K.; Arai, H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008, 10, 932-939. [CrossRef] [PubMed]
86. Rupertus, K.; Senger, S.; Menger, M.D.; Schilling, M.K.; Kollmar, O. Darbepoetin-α promotes neovascularization and cell proliferation in established colorectal liver metastases. J. Surg. Res. 2012, 176, 517-523. [CrossRef] [PubMed]
87. Nico, B.; Annese, T.; Guidolin, D.; Finato, N.; Crivellato, E.; Ribatti, D. EPO is involved in angiogenesis in human glioma. J. Neurooncol. 2011, 102, 51-58. [CrossRef] [PubMed]
88. Pascual, M.; Bohle, B.; Alonso, S.; Mayol, X.; Salvans, S.; Grande, L.; Pera, M. Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J. Surg. Res. 2013, 183, 270-277. [CrossRef] [PubMed]
89. Ribatti, D.; Marzullo, A.; Gentile, A.; Longo, V.; Nico, B.; Vacca, A.; Dammacco, F. Erythropoietin/ erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 2007, 50, 591-596. [CrossRef] [PubMed]
90. Ribatti, D.; Poliani, P.L.; Longo, V.; Mangieri, D.; Nico, B.; Vacca, A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007, 50, 636-641. [CrossRef] [PubMed]
91. Ribatti, D. Erythropoietin and tumor angiogenesis. Stem Cells Dev. 2010, 19, 1-4. [CrossRef] [PubMed]
92. Ribatti, D.; Nico, B.; Perra, M.T.; Longo, V.; Maxia, C.; Annese, T.; Piras, F.; Murtas, D.; Sirigu, P. Erythropoietin is involved in angiogenesis in human primary melanoma. Int. J. Exp. Pathol. 2010, 91, 495-499. [CrossRef] [PubMed]
93. Wang, L.; Li, H.G.; Xia, Z.S.;Wen, J.M.; Lv, J. Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma. World J. Gastroenterol. 2011, 17, 3933-3940. [CrossRef] [PubMed]
94. Han, Z.G.; Yu, T.T.; Shan, L. Expression of erythropoietin and erythropoietin receptor in non-small cell lung cancer and its correlation with microvessel density. Zhonghua Zhong Liu Za Zhi 2012, 34, 605-608. [PubMed]
95. Diensthuber, M.; Potinius, M.; Rodt, T.; Stan, A.C.;Welkoborsky, H.J.; Samii, M.; Schreyogg, J.; Lenarz, T.; Stover, T. Expression of Bcl-2 is associated with microvessel density in olfactory neuroblastoma. J. Neurooncol. 2008, 89, 131-139. [CrossRef] [PubMed]
96. Kase, S.; Osaki, M.; Jin, X.H.; Ohgami, K.; Yoshida, K.; Saito,W.; Takahashi, S.; Nakanishi, K.; Ito, H.; Ohno, S. Increased expression of erythropoietin receptor in human pterygial tissues. Int. J. Mol. Med. 2007, 20, 699-702. [PubMed]
97. Ribatti, D.; Marzullo, A.; Nico, B.; Crivellato, E.; Ria, R.; Vacca, A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 2003, 42, 246-250. [CrossRef] [PubMed]
98. Tankiewicz-Kwedlo, A.; Hermanowicz, J.; Surazynski, A.; Rozkiewicz, D.; Pryczynicz, A.; Domaniewski, T.; Pawlak, K.; Kemona, A.; Pawlak, D. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EPOR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts. Mol. Cell. Biochem. 2016, 421, 1-18. [CrossRef] [PubMed]
99. Qu, Z.; Jiang, Y.; Xu, M.; Lu, M.Z.; Zhou, B.; Ding, Y. Correlation of adrenomedullin with the erythropoietin receptor and microvessel density in hepatocellular carcinoma. Arch. Med. Sci. 2015, 11, 978-981. [PubMed]
100. Tovari, J.; Gilly, R.; Raso, E.; Paku, S.; Bereczky, B.; Varga, N.; Vago, A.; Timar, J. Recombinant human erythropoietin α targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res. 2005, 65, 7186-7193. [CrossRef] [PubMed]
101. Lee, A.S.; Kim, D.H.; Lee, J.E.; Jung, Y.J.; Kang, K.P.; Lee, S.; Park, S.K.; Kwak, J.Y.; Lee, S.Y.; Lim, S.T.; et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res. 2011, 71, 4506-4517. [CrossRef] [PubMed]